Purchase this article with an account.
Deborah A. Ferrington; Protecting the Mitochondria as a Therapeutic Strategy for dry Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1609.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Presentation Description :
Previous results from proteomic and mtDNA damage analysis have suggested that defects in the retinal pigment epithelium (RPE) mitochondria occur at an early stage of AMD. Using primary cultures of RPE from donors with or without AMD, we found that mitochondrial function is decreased in cells from donors with AMD suggesting these RPE are in a bioenergetics crisis. As a potential therapeutic treatment, we have been testing drugs that protect or improve mitochondrial function. We found large variability in the response to different mitochondrial-targeted drugs between individual donors, suggesting a need for tailoring treatment to individual patients. To provide a platform for patient-specific treatment, we have made induced pluripotent stem cells (iPSC) from biopsies of the conjunctiva and then differentiated these cells into RPE. The iPSC-RPE is used to test a battery of drugs so that the optimal drug can be selected for each patient with AMD. This is a novel system that may enable patient-specific treatment for age-related macular degeneration.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only